A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Donald Tsai, MD, PhD
Loxo Oncology
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
56 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Flinders Medical Centre
Bedford Park, South Australia, Australia
- Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
- Linear Clinical Research
Nedlands, Western Australia, Australia
- Centre Hospitalier Universitaire de Nantes - L' Hopital L'Hôtel-Dieu
Nantes, France
- Irccs - Aou Di Bologna
Bologna, Italy
- Irccs Ospedale San Raffaele
Milan, Italy
- Nagoya Medical Center
Nagoya, Aichi-ken, Japan
- Hokkaido University Hospital
Sapporo, Hokkaido, Japan
- Tokai University Hospital- Isehara Campus
Isehara, Kanagawa, Japan
- Kochi Medical School Hospital
Nankoku, Kochi, Japan
- Tohoku University Hospital
Sendai, Miyagi, Japan
- National Cancer Center Hospital
Chuo Ku, Tokyo, Japan
- National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan
- Kyoto Furitsu Medical University Hospital
Kyoto, Japan
- Okayama University Hospital
Okayama, Japan
- Kindai University Hospital
Osakasayama-Shi, Japan
- Pratia Mcm Krakow
Krakow, Poland
- Instytut Hermatologii I Transfuzjologii
Warsaw, Poland
- Samsung Medical Center
Seoul, Seoul-teukbyeolsi [Seoul], South Korea
- Seoul National University Hospital
Seoul, South Korea
- Karolinska Institutet
Solna, AB, Sweden
- Ospedale Regionale Bellinzona E Valli
Bellinzona, Canton Ticino, Switzerland
- St James'S University Hospital
Leeds, United Kingdom
- Churchill Hospital
Oxford, United Kingdom
- Derriford Hospital
Plymouth, United Kingdom
- Mayo Clinic of Scottsdale
Scottsdale, Arizona, United States
- Scripps Coastal Medical Center
San Diego, California, United States
- University of California San Francisco, Medical Center at Paranassus
San Francisco, California, United States
- Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut, United States
- Mayo Clinic-Jacksonville
Jacksonville, Florida, United States
- Florida Cancer Specialists Orlando/ddu
Lake Mary, Florida, United States
- Sylvester Comprehensive Cancer Center
Miami, Florida, United States
- Florida Cancer Specialists
Sarasota, Florida, United States
- Emory Clinic
Atlanta, Georgia, United States
- Northwestern University
Chicago, Illinois, United States
- University of Kansas Medical Center
Kansas City, Kansas, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Mayo Clinic
Rochester, Minnesota, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Mar 2019
- Primary completion
- 27 Jan 2025
- Completion
- 23 Dec 2025
- Last update posted
- 27 Jan 2026
- Registered enrollment
- 803
- Registry id
- NCT03740529
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.